Traitement Cancer du poumon en Israël — recevez 3 correspondances personnalisées de cliniques

Israeli oncologists use advanced genetic screening and biomarker analysis to determine treatment candidacy. Next-generation sequencing (NGS) identifies driver mutations like EGFR and ALK for targeted therapy. Immunotherapy eligibility depends primarily on PD-L1 expression levels and microsatellite instability (MSI) testing within JCI-accredited facilities.

• Genetic screening: Tests identify actionable mutations including ROS1, BRAF, RET, and KRAS.
• Biomarker profiling: Specialists measure PD-L1 protein expression to predict immunotherapy response.
• Liquid biopsies: Doctors use blood-based ctDNA testing if tissue samples are insufficient.
• Precision platforms: AI-driven tools like OncoHost predict immunotherapy resistance before treatment begins.
• Fitness assessment: Oncologists evaluate organ function and ECOG status to ensure safety.

Bookimed Expert Insight: Israeli oncology centres like Sheba and Sourasky serve over 400,000 patients annually, creating a massive data pool for precision medicine. Leading specialists like Dr Ofer Merimsky utilize this volume to refine treatment protocols. Their experience with over 900 procedures helps them identify which patients will benefit most from targeted drugs versus standard chemotherapy.

Patient Consensus: Patients in Israel note that comprehensive mutation testing often shifts treatment plans away from chemo. They find that confirming tissue quality early prevents the need for repeat biopsies during the diagnostic phase.

Israel offers advanced lung cancer care including immunotherapy, targeted therapy, and robotic surgery. Centres use molecular profiling to identify genetic mutations. This allows for precision medicines like osimertinib. High-tech radiation like CyberKnife and VMAT provides non-invasive options for complex or inoperable tumours.

• Precision medicine: Clinics use genomic profiling for mutations like EGFR, ALK, and KRAS.
• Immunotherapy: Access drugs like Keytruda or Opdivo to help the immune system.
• Robotic surgery: Surgeons use Da Vinci systems for precise, minimally invasive lobectomies.
• Radiosurgery: CyberKnife and SBRT deliver high-dose radiation while sparing healthy lung tissue.

Bookimed Expert Insight: Israeli oncology centres like Sheba and Sourasky serve over 1,800,000 patients annually. They often provide access to novel therapies through clinical trials before they are widely available. For instance, Dr Ofer Merimsky at Sourasky has overseen over 900 procedures. This volume ensures specialists handle even the most complex Stage IV cases with high proficiency.

Patient Consensus: Patients in Israel value the fast, integrated diagnostic work-up. They note that molecular profiling often unlocks new targeted therapy options that were not available in their home countries.

Patients can obtain a remote second opinion from Israeli specialists before travelling. Major centres use telehealth frameworks for international case reviews. Senior oncologists evaluate diagnostic files and scans via video platforms. This process confirms diagnoses and outlines advanced treatment roadmaps digitally.

• Structured review: Specialists meticulously re-evaluate raw PET-CT scans and biopsy pathology results.
• Senior expertise: Opinions often come from department heads or Forbes-listed top specialists.
• Digital framework: Consultations occur via secure video conferencing platforms like Zoom or Skype.
• Formal reports: Patients receive translated medical reports with specific treatment recommendations.

Bookimed Expert Insight: Israeli oncology centres excel at molecular matching for lung cancer. Specialists like Dr Nir Peled and Dr Jair Bar focus on specific genetic mutations. An early remote review can confirm if advanced immunotherapies like Keytruda are suitable. This often prevents unnecessary travel for patients whose cases don't require surgical intervention.

Patient Consensus: Individuals note that remote reviews provide clarity on local treatment plans versus Israeli options. Many find that sending full pathology and genetic testing results ensures the most accurate remote assessment. Patients from Australia value comparing these expert Israeli insights with their local multi-disciplinary team recommendations.

Israel's leading lung cancer oncologists include Prof. Ofer Merimsky at Sourasky Medical Center, Prof. Jair Bar at Sheba Medical Center, and Prof. Nir Peled at Herzliya Medical Center. These specialists lead major thoracic units. They focus on personalised immunotherapy and advanced targeted treatments.

• Prof. Ofer Merimsky: Heads lung cancer services at Sourasky. He has handled 900+ procedures.
• Prof. Jair Bar: Chairs the Israel Lung Cancer Group. He leads Sheba's thoracic oncology.
• Prof. Nir Peled: Specialises in immuno-oncology. He completed a lung cancer fellowship in America.
• Dr. Ari Raphael: Senior oncologist at Sourasky. He focuses on molecular profiling and immunotherapy.

Bookimed Expert Insight: Israeli oncology centres like Sheba and Sourasky serve over 400,000 patients annually. They often combine treatments into single-visit protocols. This efficiency is why medical tourists rank Israel among the top 10 global destinations. These JCI-accredited facilities offer rare specialised services like celiac plexus radiosurgery and CAR-T immunotherapy.

Patient Consensus: Patients in Israel emphasise finding specialists who join multidisciplinary tumour boards. They note it is essential to complete biomarker testing like EGFR or PD-L1 before finishing any long-term treatment plan.

Patients should plan for a total stay of 3 to 14 days in Israel for diagnostics or surgery. Complex therapies like radiotherapy or chemotherapy cycles can extend this period to 8 weeks. Specialists use JCI-accredited facilities in Tel Aviv and Haifa to manage rapid diagnostic workups.

• Diagnostic phase: Staging and multi-disciplinary board reviews typically require 3 to 7 working days.
• Surgical duration: Hospitalisation usually lasts 1 day for minimally invasive video-assisted thoracic surgery (VATS).
• Post-op monitoring: Patients must stay 6 to 10 days after discharge to ensure air-travel safety.
• Systemic therapy: Single chemotherapy or immunotherapy cycles often require a 3 to 4 week stay.

Bookimed Expert Insight: Israeli oncology centres like Sheba and Sourasky often compress multi-step diagnostics into 72 hours. While a diagnostic package may only require 5 hotel nights, patients should note that pathology record transfers can cause delays. Bringing original pathology slides from Australia or requesting digital genomic profiling interpretation in advance can shave 4 days off the initial stay.

Patient Consensus: Patients note that staging and specialist reviews take longer than expected, making flexible return flights essential. Experience at Sourasky showed that everything was organised in a timely manner, but individuals should always confirm when they are medically cleared for the long-haul flight back to Australia.